The present invention relates to a method for manufacturing an ophthalmic preparation comprising thymosin 4. According to the inventive method, the manufacture of an ophthalmic preparation comprising thymosin 4 is carried out in the presence of an inert gas, thus the contact of thymosin 4 with oxygen is blocked and the oxidation of thymosin 4 can be prevented and the pharmacological activity of thymosin 4 maintains for long-term period. Therefore, the ophthalmic preparation prepared by the inventive method can maintain the pharmacological activity of thymosin 4 in a stable state for a long time.

This disclosure provides modified cytosine deaminases (CDs). The disclosure further relates to cells and vector expressing or comprising such modified CDs and methods of using such modified CDs in the treatment of disease and disorders.

A cancer immunotherapy method for treating cancer in a patient comprising the steps of: removing lymphocytes from the peripheral blood of the patient; exposing the lymphocytes to one or more of i) a thymosin peptide, ii) a purified immune RNA or DNA. iii) one or more astragalus polysaccharides, iv) one or more letinous edodes polysaccharides, v) a cell wall component of Mycobacterium grannis, Mycobacterium phlei or Mycobaterium subtilis vi) a polysaccharide nucleic acid fraction of bacillus Calmette-Guerin, vii) a transfer factor viii) one or more non steroidal anti inflammatory agents and xi) an enkephalin chosen from methionine enkephalin or leucine enkephalin in vitro and infusing the exposed lymphocytes back into the patient is provided.

The present invention provides compositions and methods for improving cardiac function. Specifically, the present invention provides compositions and methods for treating a subject having a disorder or condition associated with aberrant cardiac tissue function, comprising contacting a patient having a disorder or condition associated with aberrant cardiac tissue function with a construct, or a construct associated with therapeutic cells, or a construct associated with fibroblast cells and therapeutic cells.

The present invention provides for a stabilized biodegradable polymeric composition useful as a controlled release delivery system for peptide agents. The compositions of the present invention comprise a) a beneficial salt of a luteinizing hormone releasing hormone (LHRH) analogue formed with a strong acid that minimizes or prevents the interaction/reaction between the LHRH and the polymer in an organic solution; b) a biodegradable polymer; c) a pharmaceutically acceptable organic solvent; and d) optionally one or more excipients. The present invention also relates to a method of manufacturing and a method of use thereof.

The present invention concerns Thymosin alpha 1 (T1) for use in treatment of cystic fibrosis as a CFTR corrector, CFTR potentiator and anti-inflammatory agent.

The present invention provides methods for preventing, treating, or reducing the severity of sepsis, severe sepsis or septic shock, including bacterial, viral, and fungal infections, and including infections of more complex etiology. The invention involves the administration of an alpha thymosin peptide regimen. In certain embodiments, the alpha thymosin peptide regimen is scheduled or timed with respect to potential, expected and/or diagnosed sepsis, severe sepsis or septic shock. In certain embodiments, the patient is immunodeficient or immunocompromised, and/or the patient is hospitalized or scheduled for hospitalization, such that the regimen of alpha thymosin peptide peptide helps to protect the patient from, or reduce the severity of, sepsis, severe sepsis or septic shock.

Provided herein is a method of treating medulloblastoma or glioblastoma in a subject by administering to the subject a PI3K activator (e.g., thymosin -4 or a derivative thereof) and one or more chemotherapeutic agents and/or radiation. The combination therapy is effective in the treatment of medulloblastoma or glioblastoma characterized by cells with elevated p53 levels.

Provided herein is a method of treating medulloblastoma or glioblastoma in a subject by administering to the subject a PI3K activator (e.g., thymosin -4 or a derivative thereof) and one or more chemotherapeutic agents and/or radiation. The combination therapy is effective in the treatment of medulloblastoma or glioblastoma characterized by cells with elevated p53 levels.

Provided herein is a method of treating medulloblastoma or glioblastoma in a subject by administering to the subject a PI3K activator (e.g., thymosin -4 or a derivative thereof) and one or more chemotherapeutic agents and/or radiation. The combination therapy is effective in the treatment of medulloblastoma or glioblastoma characterized by cells with elevated p53 levels.